Our next generation complement therapies have the potential to improve the current standard of care.

We believe small, synthetic, macrocyclic peptides have the potential to become targeted therapies for patients with a wide range of complement-mediated diseases.

Our hope is that the peptides we are developing will be found to offer clinical benefits combined with a convenient method of administration that we believe is only possible with small molecules. At Ra Pharma®, we believe that the power of peptides has the potential to change lives, and we continue to work toward our goal of unleashing that potential for patients in need.

Meet the community we are working for: